Wilson Therapeutics AB (WTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Wilson Therapeutics AB (WTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9425
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Wilson Therapeutics AB (Wilson Therapeutics), a subsidiary of Alexion Pharma Nordics AB, is a biopharmaceutical company that develops novel therapies for patients with rare copper-mediated disorders. The company’s lead product includes WTX101 is a copper-protein-binding agent, which is used for the treatment for wilson disease. Its product provides an alternative copper-protein transport mechanism, copper-protein complexes, de-toxify free copper and biliary excretion of copper. Wilson Therapeutics’ lead product is also used for the treatment of other medical conditions including amyotrophic lateral sclerosis. The company conducts clinical trials for developing the treatment of wilson disease. Wilson Therapeutics is headquartered in Stockholm, Sweden.

Wilson Therapeutics AB (WTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Wilson Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Wilson Therapeutics Acquires Decuprate from Tactic Pharma 10
Venture Financing 11
Wilson Therapeutics Raises US$40 Million In Series B Financing 11
Licensing Agreements 13
Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 13
Equity Offering 14
Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 14
Wilson Therapeutics Raises USD48 Million in IPO 16
Acquisition 18
Alexion Acquires Wilson Therapeutics for USD852 Million 18
Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 20
Wilson Therapeutics AB – Key Competitors 21
Wilson Therapeutics AB – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
May 16, 2018: Wilson Therapeutics: Interim report January 1–March 31, 2018 23
Feb 21, 2018: Wilson Therapeutics Year-End Report 2017 24
Nov 23, 2017: Wilson Therapeutics Interim Report January 1–September 30, 2017 25
Aug 24, 2017: Wilson Therapeutics: Interim Report January 1 – June 30, 2017 26
Corporate Communications 27
Jun 01, 2018: Delisting of Wilson Therapeutics 27
May 25, 2018: Wilson Therapeutics applies for delisting 28
Nov 09, 2017: Wilson Therapeutics’ Nomination Committee appointed 29
May 22, 2017: Wilson Therapeutics Strengthens its Board of Directors by the Appointments of Birgitte Volck and Bjorn Odlander 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Wilson Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Wilson Therapeutics AB, Deals By Therapy Area, 2012 to YTD 2018 8
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Wilson Therapeutics Acquires Decuprate from Tactic Pharma 10
Wilson Therapeutics Raises US$40 Million In Series B Financing 11
Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 13
Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 14
Wilson Therapeutics Raises USD48 Million in IPO 16
Alexion Acquires Wilson Therapeutics for USD852 Million 18
Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 20
Wilson Therapeutics AB, Key Competitors 21
Wilson Therapeutics AB, Subsidiaries 22

List of Figures
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Wilson Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Wilson Therapeutics AB (WTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dowa Holdings Co., Ltd.:戦略・SWOT・企業財務分析
    Dowa Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dowa Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nuo Therapeutics Inc (AURX):企業の財務・戦略的SWOT分析
    Nuo Therapeutics Inc (AURX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Phoenix Global Resources Plc (PGR):石油・ガス:M&Aディール及び事業提携情報
    Summary Phoenix Global Resources Plc (Phoenix), formerly known as Andes Energia Plc, is an upstream oil and gas company. It conducts exploration, development and production of oil and gas for conventional and unconventional resources. It has diversified portfolio of oil and gas assets in Argentina. …
  • SOCO International plc (SIA):企業の財務・戦略的SWOT分析
    Summary SOCO International Plc (SOCO) is an oil and gas company that explores, discovers and produces oil and gas reserves. The company offers appraisal and field development services. It provides training and skills and support local communities. SOCO produces and supplies natural resources. SOCO h …
  • NeuStar, Inc.:企業の戦略的SWOT分析
    NeuStar, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • NTN Corporation:企業の戦略・SWOT・財務情報
    NTN Corporation - Strategy, SWOT and Corporate Finance Report Summary NTN Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Fidelity Investments Inc:企業の戦略・SWOT・財務情報
    Fidelity Investments Inc - Strategy, SWOT and Corporate Finance Report Summary Fidelity Investments Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Andrews Sykes Group plc (ASY):企業の財務・戦略的SWOT分析
    Summary Andrews Sykes Group plc (ASG), formerly Braithwaite Plc, a subsidiary of EOI Sykes Sarl, is an environmental control equipment provider. The company hires, sells and installs air conditioning, pumps, chillers, heating, boilers, ventilation and dehumidification products. ASG products portfoli …
  • China Resources Beer (Holdings) Co Ltd:戦略・SWOT・企業財務分析
    China Resources Beer (Holdings) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Resources Beer (Holdings) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Insurance and Care NSW:企業の戦略的SWOT分析
    Insurance and Care NSW - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Bonavista Energy Corp (BNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Bonavista Energy Corp (Bonavista) is an intermediate energy company, which acquires, explores for, develops and produces oil and natural gas from its assets in the provinces of Alberta, British Columbia and Saskatchewan. Its core operations are concentrated in the Glauconite and Falher plays …
  • Caris Life Sciences Inc:企業の製品パイプライン分析
    Summary Caris Life Sciences Inc (Caris Life) is a biotechnology company. The company’s molecular scientific offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make personalized treatment decisions. Its ADAPT biotargeting system, is a plat …
  • EnerNOC, Inc.-エネルギー分野:企業M&A・提携分析
    Summary EnerNOC, Inc. (EnerNOC), formerly EnerNOC, LLC, is a provider of energy intelligence software (EIS) and demand response solutions. The company’s EIS offers enterprise customers with Software-as-a-Service (SaaS) solutions with various areas of functionalities. It offers SaaS solutions to mana …
  • Alimera Sciences Inc (ALIM):製薬・医療:M&Aディール及び事業提携情報
    Summary Alimera Sciences Inc (Alimera) is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabet …
  • InMed Pharmaceuticals Inc (IN)-製薬・医療分野:企業M&A・提携分析
    Summary InMed Pharmaceuticals Inc (InMed), formerly Cannabis Technologies Inc, is a pre-clinical stage biopharmaceutical company which develops, produces and markets plant cannabinoid based pharmaceutical products to related healthcare markets. The company's pipeline products include INM-750 and INM …
  • The US Oncology Network:企業の戦略的SWOT分析
    The US Oncology Network - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Pilot Energy Ltd (PGY):電力:M&Aディール及び事業提携情報
    Summary Pilot Energy Ltd (Pilot), formerly Rampart Energy Ltd is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in Australia. Its projects include Australia EP416 and EP480, Australia WA-507-P, Australia WA-503-P and Aus …
  • High-Tech Grunderfonds Management GmbH:企業のM&A・事業提携・投資動向
    High-Tech Grunderfonds Management GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's High-Tech Grunderfonds Management GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • Fanuc Corp (6954)
    Fanuc Corp (6954) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Dongbu HiTek Co., Ltd. (000990):企業の財務・戦略的SWOT分析
    Dongbu HiTek Co., Ltd. (000990) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆